← Back to all trials
Completed
NCT05857566
Effect of RDX-002 on Postprandial Triglycerides in Subjects Treated With Olanzapine
Conditions: Drug-induced Weight Gain
Sex: All
Ages: 18 Years – 50 Years
Healthy volunteers: Yes
Phase: PHASE1
Enrollment: 24
Sponsor: Response Pharmaceuticals
Location: Nucleus Network Saint Paul Minnesota
Summary
This Phase 1b Study RDX-002-22-09 has been planned to evaluate the effect of RDX-002 on postprandial triglycerides and ApoB48 levels in normal healthy subjects treated with the atypical antipsychotic drug, olanzapine.
Eligibility Criteria
Inclusion Criteria:
* A glycated hemoglobin (HbA1c) level of \
Source: ClinicalTrials.gov (NCT05857566). StuddyBuddy aggregates publicly available trial information.